EUVIMEDEUVIMED entdecken
Crossref

Prevalence of Primary Aldosteronism Among Patients With Hypertension

Divyansh Goyal, Manasvini Bhatt, Tamoghna Ghosh, Prayas Sethi, Ranveer Singh Jadon, Sarah Alam, Rajesh Khadgawat iD

Clinical Endocrinology · 2025

DOI: 10.1111/cen.15296 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von Divyansh Goyal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Hyperaldosteronism, Hypertension. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite being a leading cause of secondary hypertension and association with a higher incidence of cardiovascular morbidity and mortality the prevalence of primary aldosteronism (PA) is poorly studied.

Objective

We assessed the prevalence of PA in participants being treated as essential hypertension (EHTN). Design and Participants In this prospective, cross‐sectional study, 492 participants with diagnosis of EHTN were evaluated. The screening for PA was conducted by measuring plasma aldosterone concentration (PAC) and direct renin concentration (DRC), from which the aldosterone‐to‐renin ratio (ARR) was calculated. Based on Endocrine Society guidelines, screening test was followed by a confirmatory recumbent saline infusion test (SIT). Participants who showed a post‐SIT PAC greater than 5 ng/dL were diagnosed with PA.

Results

Of 492 EHTN participants, 91 (18.49%) had positive screening test. Out of 91 participants, 59 agreed for SIT and PA was confirmed in 37 participants (8.04%) (Excluding 32 screened positive participants who were non‐compliant to SIT). The mean age was 49.98 ± 7.76 years, and median duration of hypertension was 5 (0−24) years. The prevalence of PA increased with grade of hypertension (5.97% in grade 1%−12.03% in grade 3), hypertension daily dose (HDD) (3.57% in those with HDD < 1% to 27.27% in those with HDD ≥ 4). No significant difference in hypokalaemia in PA and EHTN (2.70% and 3.54% respectively, p : 0.7815).

Conclusions

Our study shows a high prevalence of PA in subjects treated as a case of EHTN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperaldosteronismHypertensionHumansMiddle AgedMaleFemalePrevalenceCross-Sectional StudiesProspective StudiesAdultAldosteroneRenin

Stichwörter der Autor:innen

hypertensionplasma aldosteroneprimary hyperaldosteronism

Substanzen

AldosteroneRenin

Autor:innen und Institutionen

  • Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.
  • All India Institute of Medical Sciences, New Delhi, India.
  • Department of Endocrinology and Metabolism, Canadian Specialist Hospital, Dubai, UAE.

ORCID-Profile: Rajesh Khadgawat

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Goyal, D., Bhatt, M., Ghosh, T., Sethi, P., Jadon, R. S., Alam, S., & Khadgawat, R. (2025). Prevalence of Primary Aldosteronism Among Patients With Hypertension. Clinical Endocrinology. https://doi.org/10.1111/cen.15296

Vancouver

Goyal D, Bhatt M, Ghosh T, Sethi P, Jadon RS, Alam S, et al. Prevalence of Primary Aldosteronism Among Patients With Hypertension. Clinical Endocrinology. 2025. doi:10.1111/cen.15296

BibTeX
@article{Goyal2025,
  author = {Goyal, Divyansh and Bhatt, Manasvini and Ghosh, Tamoghna and Sethi, Prayas and Jadon, Ranveer Singh and Alam, Sarah and Khadgawat, Rajesh},
  title = {Prevalence of Primary Aldosteronism Among Patients With Hypertension},
  journal = {Clinical Endocrinology},
  year = {2025},
  doi = {10.1111/cen.15296}
}
Kostenlos starten →